Loading...
Market
Which major pharmaceutical company will partner with Butantan Institute for Butantan-DV by the end of 2025?
3
Resolution / Starting Odds
Pfizer • 25%
Johnson & Johnson • 25%
Sanofi • 25%
Other • 25%
Press releases or official announcements from pharmaceutical companies or the Butantan Institute
Story
Butantan Requests Anvisa Approval for Butantan-DV, World's First Single-Dose Dengue Vaccine by 2025
Dec 16, 2024, 01:14 PM
The Butantan Institute has formally requested the Brazilian Health Regulatory Agency (Anvisa) to approve the world's first single-dose vaccine against dengue. This vaccine, known as Butantan-DV, aims to enhance immunization efforts, particularly as the Health Ministry plans to introduce dengue vaccination in schools by 2025. The subsecretary of Health Surveillance emphasized the goal of increasing vaccination coverage against dengue in the coming years. The approval from Anvisa is now awaited to proceed with the rollout of this innovative vaccine.
View original story
Similar markets
Argentina • 25%
Mexico • 25%
India • 25%
Other • 25%
Approved • 25%
Rejected • 25%
Pending • 25%
Withdrawn • 25%
0 • 25%
1 to 5 • 25%
6 to 10 • 25%
More than 10 • 25%
United States • 25%
European Union • 25%
India • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
AstraZeneca • 25%
Other • 25%
Yes • 50%
No • 50%
Argentina • 25%
Mexico • 25%
Colombia • 25%
Other • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Pfizer • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%
No partnership • 25%